Compare · AUTL vs XBIO

AUTL vs XBIO

Side-by-side comparison of Autolus Therapeutics plc (AUTL) and Xenetic Biosciences Inc. (XBIO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. AUTL focuses on Biotechnology: Biological Products (No Diagnostic Substances), while XBIO focuses on Biotechnology: Pharmaceutical Preparations.
  • AUTL is the larger of the two at $261.0M, about 72.3x XBIO ($3.6M).
  • AUTL has been more active in the news (13 items in the past 4 weeks vs 6 for XBIO).
  • AUTL has more recent analyst coverage (7 ratings vs 0 for XBIO).
MetricAUTLXBIO
Company
Autolus Therapeutics plc
Xenetic Biosciences Inc.
Price
-
-
Market cap
$261.0M
$3.6M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2018
News (4w)
13
6
Recent ratings
7
0
AUTL

Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.

XBIO

Xenetic Biosciences Inc.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Latest AUTL

Latest XBIO